Deal of the Day — limited-time pharmacy picks!
Gefitero 250mg Tablet

Gefitero 250mg Tablet

Prescription requiredRx Required

Salt Composition: Gefitinib

Expiry Date: 01/2028

Special offer

Buy at $14.14

$14.14

Inclusive of all taxes

▼

10 tablet

About The Product

non-small cell lung cancer (NSCLC)

Gefitero 250mg tablet is a chemotherapy medication that is used in the treatment of non-small cell lung cancer (NSCLC). The generic name of this medication is Gefitinib.

It is a tyrosine kinase inhibitor that shows antineoplastic activity. Gefticip is used in the first-line treatment of lung cancer that has genetic mutations.

Uses

Used to manage adults with non-small cell lung cancer

Side Effects

Gefitero 250mg Tablet may cause certain side effects. If side effects occur after administration or last longer than usual, contact your healthcare professional.


  • Diarrhea
  • Fever
  • Allergic skin reaction
  • Nausea and Vomiting
  • Increase in liver enzyme levels
  • Eye irritation
  • Difficulty in breathing
  • Abdominal pain
  • Sore throat
  • Redness around fingernails
  • Unusual bleeding (in cough and urine), eye irritation or swelling of the ankles or feet ​

How To Use

  • Depending on your health and body tolerance, the doctor will advise you on the dosage strength and frequency.
  • Consume the entire ​Gefitero 250mg Tablet with water.
  • Avoid cutting or crushing it.
  • In a case of an overdose, seek immediate medical attention and get in touch with your doctor.

How It Works

Gefitero 250mg tablet is an anticancer medicine that contains gefitinib as an active ingredient.

It works by blocking the action of a protein known as epidermal growth factor receptor (EGFR) that is responsible for the growth and multiplication of certain cancer cells.

Results in slowing down the progression of non-small cell lung cancer in patients with specific EGFR gene mutations.


Safety Advice

Alcohol
It is advisable not to consume alcohol while taking this medicine. Alcohol use and the Gefitero 250mg Tablet may interact, although this is not certain. Kindly get more guidance from your physician.
Pregnancy
Do not take Gefitero 250mg Tablet without consulting the doctor, in case of pregnancy. There is clear evidence of a risk to the developing embryo; Gefitero Tablet should not be used during pregnancy. In certain life-threatening situations, however, if the benefits are greater than the possible risks, the doctor might sometimes recommend it. Please speak with your physician.
Breast Feeding
Without a doctor's consultation, do not take this medicine if you're breastfeeding. Because it is unknown whether gefitinib goes into breast milk, you should not breastfeed while taking this medication.
Driving
It is advisable not to drive or operate heavy machinery, you may feel dizzy as one of the side effects of the medicine.
Kidney
Do not take Gefitero 250mg Tablet without a doctor's consultation in case of kidney problems.
Liver
Share your medical history with the doctor in case of liver disease before taking this medicine. It is advised to use the Gefitero 250mg Tablet with caution if you have liver problems. The liver metabolizes this medication, which may have an impact on liver function. Before beginning this drug, it is advisable to speak with your doctor.

Missed Doses

  • ​ If a patient misses a dose of medicine, skip it and continue with the normal schedule.
  • No need to double the dose ​

FAQs

​ Gefitero 250 mg Tablet is an anticancer medicine used for the treatment of cancer of the lungs. Take the medicine under the supervision of a qualified physician.

This medicine is not recommended for use in patients with lung and liver diseases. ​

Reference

Fukuoka. M., Yano. S., Giaccone. G., Tamura. T. Nakagawa. K., Douillard. J.‑Y., Nishiwaki. Y., Vansteenkiste. J., Kudoh. S., & Mizuuchi. H. (2024). Multi‑institutional randomized Phase II trial of gefitinib (Iressa, ZD1839) for previously treated patients with advanced non‑small‑cell lung cancer (IDEAL‑1). Journal of Clinical Oncology, 22(11), 2231–2239 - https://pubmed.ncbi.nlm.nih.gov/12748244/

Saraswati. E. N., Wulandari. L., Erawati. D., & Febriani. A. (2024). Comparison between the originator and me‑too drugs of first‑generation EGFR‑TKI in EGFR‑mutant NSCLC patients: A retrospective cohort study. International Journal of Research Publications. 147(1), 236–244.


Sim. E. H. A., Yang. I. A., Wood‑Baker. R., Bowman. R. V., & Fong. K. M. (2025). Gefitinib for advanced non‑small cell lung cancer. Cochrane Database of Systematic Reviews. 1(1),  https://doi.org/10.1002/14651858.


Wo. H., He. J., Zhao. Y., Yu. H., Chen. F., Yi. H. (2018). The Efficacy and Toxicity of Gefitinib in Treating Non-small Cell Lung Cancer: A Meta-analysis of 19 Randomized Clinical Trials. Journal of Cancer, 9(8), 1455-1465 - https://pmc.ncbi.nlm.nih.gov/articles/PMC5929091/


Xu. J.‑M., Li. Y.‑M., Liu. X.‑Q., Zhang. Y., Han. Y., Yang. W.‑W., & Song. S.‑T. (2024). Clinical observation of gefitinib for the treatment of 125 cases with advanced non‑small cell lung cancer. Zhonghua Zhong Liu Za Zhi. 29(1), 66–69.

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026